ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.61
0.20%
US Tech 100
18,146.00
0.17%
S&P 500
5,308.15
1.17%
US Dollar vs CAD
1.36215
0.18%
Bitcoin
66,193.77
-0.10%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Medicinova Inc (MNOV)

  7. Medicinova Inc (MNOV) News

MNOV

Medicinova (MNOV)

Medicinova Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MNOV
DateTimeSourceHeadlineSymbolCompany
05/14/20245:00AMGlobeNewswire Inc.MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeNASDAQ:MNOVMedicinova Inc
05/09/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNOVMedicinova Inc
05/07/20245:00AMGlobeNewswire Inc.MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)NASDAQ:MNOVMedicinova Inc
04/02/20246:00PMGlobeNewswire Inc.MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)NASDAQ:MNOVMedicinova Inc
03/26/20246:00PMGlobeNewswire Inc.MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanNASDAQ:MNOVMedicinova Inc
03/20/20246:00PMGlobeNewswire Inc.MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyNASDAQ:MNOVMedicinova Inc
03/12/20245:30AMGlobeNewswire Inc.MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyNASDAQ:MNOVMedicinova Inc
02/15/20243:25PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MNOVMedicinova Inc
01/19/20243:27PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MNOVMedicinova Inc
01/19/20243:25PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MNOVMedicinova Inc
01/19/20243:23PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MNOVMedicinova Inc
01/19/20243:21PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MNOVMedicinova Inc
01/17/20245:00AMGlobeNewswire Inc.MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaNASDAQ:MNOVMedicinova Inc
01/11/20243:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNOVMedicinova Inc
01/11/20243:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNOVMedicinova Inc
01/11/20243:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNOVMedicinova Inc
12/21/20235:00PMGlobeNewswire Inc.MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyNASDAQ:MNOVMedicinova Inc
12/06/20235:00PMGlobeNewswire Inc.MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeNASDAQ:MNOVMedicinova Inc
11/20/20236:42AMIH Market NewsStocks Set to Open Higher as Investors Await FOMC Minutes and Nvidia EarningsNASDAQ:MNOVMedicinova Inc
11/19/20235:00PMGlobeNewswire Inc.MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyNASDAQ:MNOVMedicinova Inc
11/09/20233:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNOVMedicinova Inc
10/27/202312:00AMGlobeNewswire Inc.MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaNASDAQ:MNOVMedicinova Inc
10/10/20236:00PMGlobeNewswire Inc.MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaNASDAQ:MNOVMedicinova Inc
10/04/20236:00PMGlobeNewswire Inc.MediciNova Receives Gene Therapy Milestone PaymentNASDAQ:MNOVMedicinova Inc
09/27/20236:00PMGlobeNewswire Inc.MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryNASDAQ:MNOVMedicinova Inc
08/17/20236:00PMGlobeNewswire Inc.MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-OncologyNASDAQ:MNOVMedicinova Inc
08/16/20236:00PMGlobeNewswire Inc.MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in EuropeNASDAQ:MNOVMedicinova Inc
08/15/20236:00PMGlobeNewswire Inc.MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in EuropeNASDAQ:MNOVMedicinova Inc
08/14/20236:00PMGlobeNewswire Inc.MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in EuropeNASDAQ:MNOVMedicinova Inc
08/09/20233:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNOVMedicinova Inc
 Showing the most relevant articles for your search:NASDAQ:MNOV

Your Recent History

USOTC
RXMD
Progressive Care (QB)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
IQST
iQSTEL (QX)
USOTC
HNRC
Houston Natural Resources (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
EPAZ
Epazz (PK)
AMEX
SPY
SPDR S&P 500
USOTC
CGAC
Code Green Apparel (PK)
USOTC
IBGR
Nexus Energy Services (PK)
USOTC
FBEC
FBEC Worldwide (CE)
USOTC
SPZI
Spooz (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
MVNT
Movement Industries (PK)
USOTC
TDRK
TideRock Companies (PK)
USOTC
SAPX
Seven Arts Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved